Elucidata
Elucidata, founded by Abhishek Jha and Swetabh Pathak, is a data-first AI company specializing in accelerating life sciences R&D by converting fragmented biomedical datasets into harmonized, AI-ready assets.
Profile
Elucidata transforms fragmented biomedical data into AI-ready assets for life sciences research and drug discovery.
Elucidata, founded by Abhishek Jha and Swetabh Pathak, is a data-first AI company specializing in accelerating life sciences R&D by converting fragmented biomedical datasets into harmonized, AI-ready assets. Headquartered in San Francisco with additional R&D hubs in Boston and India, the company operates with a multidisciplinary team of over 170 professionals. Elucidata’s proprietary platform, Polly, integrates EHRs, genomics, imaging, and clinical trial data to enable seamless downstream analysis and model development.
The company has gained traction with over 100 pharmaceutical and diagnostic companies, supporting 40+ programs at IND or later stages. In 2025, Elucidata announced a strategic partnership with Sapien Biosciences to transform biobank assets into high-quality AI products, leveraging Sapien’s repository of over 300,000 patient samples. This collaboration underscores Elucidata’s focus on turning real-world patient data into actionable insights for precision medicine.
The company has also been recognized for its leadership in data-centric AI, ranking 7th in the Broad Institute’s Autoimmune Disease Machine Learning Challenge and winning the National Cancer Institute's Cancer Research Data Commons AI Data Readiness Challenge. In January 2026, Elucidata launched its AI Lab, focusing on solving out-of-distribution (OOD) problems in biomedical R&D, aiming to build AI systems that detect and operationalize edge-case signals.
Who buys this
- Pharmaceutical companies
- Biotechnology firms
- Healthcare providers
- Diagnostic companies
- Agricultural technology companies
Publicly disclosed clients
- Alnylam
- Owkin
- Eli Lilly and Company
- Bristol Myers Squibb
- Janssen
- DeepMind
- Atavistik
Strengths and what to watch
Strengths
- Proprietary Polly platform integrates diverse biomedical data types
- Strong partnerships with leading biopharma companies
- Focus on solving out-of-distribution problems in AI
Watch for
- High dependency on partnerships for data access
- Challenges in scaling AI solutions across diverse biomedical domains
- Potential regulatory hurdles in data integration and AI deployment
Recent moves
Key Information
- Founded
- 2015
- Headquarters
- San Francisco
Frequently Asked Questions
What does Elucidata do?
Elucidata transforms fragmented biomedical data into AI-ready assets for life sciences research and drug discovery. Their proprietary platform, Polly, integrates EHRs, genomics, imaging, and clinical trial data to enable seamless downstream analysis and model development.
What is Elucidata's Polly platform?
Elucidata’s Polly platform integrates diverse biomedical data types, including EHRs, genomics, imaging, and clinical trial data. It harmonizes fragmented datasets into AI-ready assets, enabling seamless downstream analysis and model development for life sciences research and drug discovery.
Who are Elucidata's notable clients?
Elucidata serves over 100 pharmaceutical and diagnostic companies, including notable clients like Alnylam, Owkin, Eli Lilly, Bristol Myers Squibb, Janssen, DeepMind, and Atavistik. These partnerships support 40+ programs at IND or later stages.
What is Elucidata's partnership with Sapien Biosciences?
Elucidata partnered with Sapien Biosciences in 2025 to transform biobank assets into high-quality AI products. This collaboration leverages Sapien’s repository of over 300,000 patient samples to turn real-world data into actionable insights for precision medicine.
What is Elucidata's AI Lab?
Elucidata launched its AI Lab in January 2026 to solve out-of-distribution problems in biomedical R&D. The lab focuses on building AI systems that detect and operationalize edge-case signals, advancing precision medicine and drug discovery.
How does Elucidata support drug discovery?
Elucidata accelerates drug discovery by converting fragmented biomedical datasets into harmonized, AI-ready assets. Their Polly platform integrates EHRs, genomics, imaging, and clinical trial data, enabling seamless downstream analysis and model development for pharmaceutical and diagnostic companies.
Sources
- www.businesswire.com — Strategic partnership with Sapien Biosciences
- www.businesswire.com — Launch of AI Lab
- www.elucidata.io — Company overview and product details
- techcrunch.com — Historical acquisition context